✦ LIBER ✦

Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer

✍ Scribed by Ian D DAVIS; Guy TONER; Adam BROAD; Louise M CAMPANO; Mark ROSENTHAL

Book ID: 111318643
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 171 KB
Volume: 3
Category: Article
ISSN: 1743-7555
DOI: 10.1111/j.1743-7563.2007.00101.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of granulocyte-macrophage

Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate

✍ Robert J. Amato; Joan Hernandez-McClain; Haby Henary 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 71 KB

113 POSTER Phase II trial to assess the

113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax®) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)

✍ R. Amato; M. Karediy; A. Cao; M. Khan; S. Naylor; M. McDonald; R. Harrop; W. Shi 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A Phase II study of estramustine, doceta

A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813

✍ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor (G‐CSF) support in patients with hormone‐refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,